Select Language
TIM-3
TIM-3 Overview
| English Name | Hepatitis A virus cellular receptor 2 | Approved Drugs | 0 |
| Drugs in Clinical Trials | 22 | Target Synonym | T-cell immunoglobulin mucin receptor 3，T-cell membrane protein 3，TIMD3，T-cell immunoglobulin and mucin domain-containing protein 3，HAVcr-2，TIM-3，CD366，HAVCR2，Hepatitis A Virus Cellular Receptor 2，T-Cell Immunoglobulin Mucin Family Member 3，TIMD-3，TIM3，T Cell Immunoglobulin Mucin 3，Kidney Injury Molecule-3，KIM-3，FLJ14428，CD366 Antigen，SPTCL |
| Highest Development Stage | Phase 3 Clinical | ||
| English Name | Hepatitis A virus cellular receptor 2 |
| Target Synonym | T-cell immunoglobulin mucin receptor 3，T-cell membrane protein 3，TIMD3，T-cell immunoglobulin and mucin domain-containing protein 3，HAVcr-2，TIM-3，CD366，HAVCR2，Hepatitis A Virus Cellular Receptor 2，T-Cell Immunoglobulin Mucin Family Member 3，TIMD-3，TIM3，T Cell Immunoglobulin Mucin 3，Kidney Injury Molecule-3，KIM-3，FLJ14428，CD366 Antigen，SPTCL |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 22 |
| Highest Development Stage | Phase 3 Clinical |
TIM-3 Product List
- Product Category
Protein (11)Antibody (1)
- Product Status
Launched (12)
- Species
Human (5)Mouse (3)Cynomolgus (2)Canine (1)Rabbit (1)
- Tag
His Tag (4)Fc Tag (3)His Tag & Avi Tag (2)Mouse IgG Fc Tag (1)Fc Tag & Avi Tag (1)- (1)
- Conjugate
Unconjugated (8)Biotin-labeled (3)PE Labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT TI3-H82F8 |  Human | HEK293 | Biotinylated Human TIM-3 / HAVCR2 Protein, Fc,Avitag™ (MALS verified) |  |  |  |
HOT TM3-H5229 | Human | HEK293 | Human TIM-3 / HAVCR2 Protein, His Tag (MALS verified) |  | | |
HOT TM3-H82E7 | Human | HEK293 | Biotinylated Human TIM-3 / HAVCR2 Protein, Avitag™,His Tag (MALS verified) |  | | |
HOT TI3-M82E3 |  Mouse | HEK293 | Biotinylated Mouse TIM-3 / HAVCR2 Protein, His,Avitag™ (HPLC verified) |  | | |
HOT TI3-C52H4 |  Cynomolgus | HEK293 | Cynomolgus TIM-3 / HAVCR2 Protein, His Tag |  | | |
TM3-H5258 | Human | HEK293 | Human TIM-3 / HAVCR2 (22-200) Protein, Fc Tag (MALS verified) |  | | |
TM3-H525b | Human | HEK293 | Human TIM-3 / HAVCR2 Protein, Mouse IgG2a Fc Tag, low endotoxin |  | | |
TI3-M5252 | Mouse | HEK293 | Mouse TIM-3 / HAVCR2 Protein, Fc Tag |  | | |
TI3-M52H1 | Mouse | HEK293 | Mouse TIM-3 / HAVCR2 Protein, His Tag |  | | |
FABm042-01 |  Rabbit | HEK293 | PE-Labeled Monoclonal Anti-Human TIM-3 Antibody, Rabbit IgG (M1G07) (0.03% Proclin) |  |
Total: 12
- 1
- 2
TIM-3 Synonyms
HAVCR2,TIM3,TIMD3,FLJ14428,KIM3
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Cobolimab | WBP 296A; TSR-022; GSK-4069889 | Phase 3 Clinical | Anaptysbio Inc | Liver Neoplasms; Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Sabatolimab | MBG-453; NVP-MBG453 | Phase 3 Clinical | Novartis Pharma Ag | Leukemia, Myelogenous, Chronic; Leukemia; Preleukemia; Hematologic Diseases; Leukemia, Myeloid; Polycythemia Vera; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Glioblastoma; Neoplasms; Primary Myelofibrosis; Bone Marrow Diseases; Leukemia, Myeloid, Acute; Thrombocythemia, Essential | Details |
| Surzebiclimab | BGB-A425 | Phase 2 Clinical | BeOne Medicines Ltd | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| Lomvastomig | RG-7769; RO-7121661; R07121661 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| BMS-986258 | ONO-7807; BMS-986258 | Phase 2 Clinical | Five Prime Therapeutics Inc, Bristol-Myers Squibb Company | Neoplasms | Details |
| Sabestomig | AZD-7789 | Phase 2 Clinical | AstraZeneca Ag | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| S-095018 | S095018; S-095018 | Phase 2 Clinical | Servier Bio-Innovation LLC, Institut De Recherches Internationales Servier, Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung | Details |
| Anti Tim-3/CD123 CAR-T Cell Therapy(Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu), The Affiliated Hospital Of Xuzhou Medical University | Leukemia, Myeloid, Acute | Details | |
| LB-1410 | LB-1410 | Phase 2 Clinical | L&L Biopharma Co Ltd | Solid tumours; Neoplasms; Lymphoma | Details |
| TB-006 | TB-006; TB006 | Phase 2 Clinical | TrueBinding Inc | Autism Spectrum Disorder; Coronavirus Disease 2019 (COVID-19); Alzheimer Disease; Parkinson Disease; Ischemic Stroke | Details |
| BC-3402 | BC-3402; BC3402 | Phase 2 Clinical | Wuxi BioCity | Hematologic Neoplasms; Solid tumours; Hematologic Diseases; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Carcinoma, Hepatocellular | Details |
| TQB-2618 | TQB-2618 | Phase 2 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Myelodysplastic Syndromes; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Leukemia, Myeloid, Acute; Lymphoma; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular; Melanoma | Details |
| SHR-1702 | SHR-1702 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| LY-3321367 | LY-3321367 | Phase 1 Clinical | Eli Lilly And Company | Solid tumours | Details |
| TIM-3 checkpoint inhibitor (Bristol-Myers Squibb) | Phase 1 Clinical | Five Prime Therapeutics Inc | Neoplasms | Details | |
| KL-A293 | KL-A293 | Phase 1 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Neoplasms | Details |
| NB-002 (Suzhou Luosheng Bio-Pharmaceutical) | NB-002 (Suzhou Luosheng Bio-Pharmaceutical); NB-002 (逻晟生物); NB-002 | Phase 1 Clinical | NeoLogics Bioscience Co Ltd | Solid tumours; Neoplasms | Details |
| LPX-TI641 | LPX-TI-641 | Phase 1 Clinical | LAPIX Therapeutics Inc | Autoimmune Diseases; Arthritis, Rheumatoid; Multiple Sclerosis; Neuromyelitis Optica; Demyelinating Diseases; Arthritis, Psoriatic | Details |
| Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals) | Bis-5 | Phase 1 Clinical | L&L Biopharma Co Ltd | Solid tumours; Neoplasms | Details |
| LBL-003 | LBL-003 | Phase 1 Clinical | Nanjing WeiLibo biological Technology Co Ltd | Neoplasms | Details |
| Sym-023 | Sym-023; Sym023; S95018 | Phase 1 Clinical | Symphogen A/S | Solid tumours; Lymphoma; Neoplasm Metastasis | Details |
| WBP-3425 | WBP-3425 | Phase 1 Clinical | Wuxi BioCity | Solid tumours; Colonic Neoplasms | Details |
- Overview
- Product List
- Clinical Drug Information
Share to:
Online Message
Contact Us
BettinastraBe 30, 60325 Frankfurt am Main